RT Journal Article
SR Electronic
T1 SMOOTH protocol: A pilot randomised prospective intra-patient single-blinded observational study for examining the mechanistic basis of ablative fractional carbon dioxide laser therapy in treating hypertrophic scarring
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.19.23288792
DO 10.1101/2023.04.19.23288792
A1 Chen, Yung-Yi
A1 Patel, Krupali M.
A1 Imran, Rizwana
A1 Hassouna, Tarek
A1 Amirize, Ezekwe
A1 Abdulsalam, Abdulrazak
A1 Bishop, Jonathan
A1 Slade, Anita
A1 Ventura, Maximina
A1 Yarrow, Jeremy
A1 Lord, Janet M.
A1 Wilson, Yvonne
A1 Moiemen, Naiem S.
YR 2023
UL http://medrxiv.org/content/early/2023/04/20/2023.04.19.23288792.abstract
AB Background Burn injuries are the fourth most common type of trauma and are associated with substantial morbidity and mortality. The impact of burn injury is clinically significant as burn injuries often give rise to exuberant scarring. Hypertrophic scarring (HTS) is a particular concern as up to 70% of burns patients develop HTS. Laser therapy is used for treating HTS and has shown positive clinical outcomes, although the mechanisms remain unclear limiting approaches to improve its effectiveness. Emerging evidence has shown that fibroblasts and senescent cells are important modifiers of scarring. This study aims to investigate the cellular kinetics in HTS after laser therapy, with a focus on the association of scar reduction with the presence of senescent cells.Methods We will conduct a multicentre, intra-patient, single-blinded, randomised controlled longitudinal pilot study with parallel assignments to achieve this objective. 60 participants will be recruited to receive 3 interventional ablative fractional CO2 laser treatments over a 12-month period. Each participant will have two scars randomly allocated to receive either laser treatment or standard care. Biopsies will be obtained from laser-treated, scarred- no treatment and non-scarred tissues for immune-histological staining to investigate the longitudinal kinetics of p16INK4A+-senescent cells and fibroblast subpopulations (CD90+/Thy1+ and αSMA+). Combined subjective scar assessments including Modified Vancouver Scar Scale, Patient and Observer Scar Assessment Scale and Brisbane Burn Scar Impact Profile; and objective assessment tools including 3D-Vectra-H1 photography, DermaScan® Cortex, Cutometer® and ColoriMeter®DSMIII will be used to evaluate clinical outcomes. These will then be used to investigate the association between senescent cells and scar reduction after laser therapy. This study will also collect blood samples to explore the systemic biomarkers associated with the response to laser therapy.Discussion This study will provide an improved understanding of mechanisms potentially mediating scar reduction with laser treatment, which will enable better designs of laser treatment regimens for those living with HTS.Trial registration ClinicalTrials.gov: NCT04736251.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov: NCT04736251Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04736251 Funding StatementThis work is supported by the Chancellor using LIBOR funds via a grant obtained by The Scar Free Foundation https://scarfree.org.uk/ The award was received by NM. The funders did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SMOOTH Study is conducted according to the Declaration of Helsinki (2008). It received favourable opinion on from the North Scotland Research Ethics Committee (REC reference: 19/NS/0125). Consequently, on 22nd September 2022, the Health Research Authority (HRA) and Health and Care Research Wales (HCRW) issued the approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo datasets were generated or analysed in the current study protocol. Deidentified research data will be disseminated via peer-reviewed publication and presentations at national and international conferences once the study is completed.